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Abstract
Our objective was to assess predictors of self-reported opioid use among patients with back pain due
to lumbar disc herniation or spinal stenosis. Data was from the Spine Patient Outcomes Research
Trial (SPORT), a multi-site observational study and randomized trial. We examined characteristics
shown or hypothesized to be associated with opioid use. Using generalized estimating equations, we
modeled associations of each potential predictor with opioid use at 12 and 24 months. At baseline,
42% of participants reported opioid use. Of these participants, 25% reported continued use at 12
months and 21% reported use at 24 months. In adjusted models, smoking (RR=1.9, p<0.001 at 12
months; RR=1.5, p=0.043 at 24 months) and non-surgical treatment (RR=1.7, p<0.001 at 12 months;
RR=1.8, p=0.003 at 24 months) predicted long-term opioid continuation. Among participants not
using opioids at baseline, incident use was reported by 8% at 12 and 7% at 24 months. We found no
significant predictors of incident use at 12 or 24 months in the main models. In conclusion,
nonsurgical treatment and smoking independently predicted long-term continued opioid use. To our
knowledge, this is the first longitudinal study to assess predictors of long-term and incident opioid
use among patients with lumbar spine conditions.
INTRODUCTION
Opioid analgesic prescribing for chronic noncancer-related pain, including back pain, has
increased in recent years.5;19;22;35 This trend has occurred despite limited evidence for the
long-term effectiveness of opioids in chronic back pain.20 Consensus on appropriate
prescribing is lacking; some experts advocate greater use of opioids in noncancer pain, whereas
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others recommend an opioid-sparing approach. As a result, long-term opioid use for noncancer
pain remains controversial and prescribing practices vary substantially.19;22;27;35
The published literature provides little evidence about which patients are most likely to benefit
from long-term opioid treatment. However, observational studies have identified some patient
characteristics that are associated with negative outcomes; for example, patients with mental
and substance use disorders appear to be at higher risk for developing problematic opioid use
or addiction in the setting of long-term opioid therapy.10;15
Some cross-sectional studies have found that opioid prescribing is associated with greater pain
severity and pain-related clinical findings.13;24 In contrast, others have found that opioid
prescribing is more strongly associated with mental health disorders, problem drug use, and
pain behaviors than with pain severity or clinical findings.4;25;28 A nationally-representative
longitudinal survey of the general population (including individuals with and without pain)
found that problem drug use and the presence of a mental disorder predicted prescription opioid
use, even after controlling for pain interference and the presence of a pain condition.26 No
published prospective longitudinal studies have assessed predictors of opioid use in patients
with specific pain conditions.
Our objective was to assess predictors of long-term opioid use among patients with back pain
related to specific lumbar spine conditions. Using longitudinal data from the Spine Patient
Outcomes Research Trial (SPORT), we compared characteristics of opioid users and non-users
at baseline and assessed predictors of self-reported continued and incident opioid use over two
years of follow-up.
METHODS
We conducted a secondary analysis of data from SPORT, a parallel observational cohort and
randomized trial comparing surgical with non-surgical treatment for patients with back pain
and associated leg symptoms due to three lumbar spine conditions: intervertebral disc
herniation (IDH), spinal stenosis (SpS), and spinal stenosis with degenerative spondylolisthesis
(DS). SPORT methods have been described in detail elsewhere and are summarized briefly in
the following sections.3
Participants and procedures
Participants were recruited from 13 spine specialty centers in 11 different US states. Eligible
patients were adults with IDH, SpS, or DS, as determined by the presence of an appropriate
clinical presentation, examination findings, and imaging results. Exclusion criteria included
prior spine surgery; inadequate trial of nonsurgical therapy (< 6 weeks for IDH and <12 weeks
for SpS/DS); presence of a contraindication to surgery or indication for urgent surgery; active
cancer; and fracture, infection, or significant deformity of the spine. Institutional review boards
at each participating site approved the protocol and all participants gave informed consent.
Eligible patients who agreed to randomization enrolled in the randomized controlled trial; those
who agreed to participate but declined randomization enrolled in the parallel observational
cohort study. Other than randomization to surgical vs. nonsurgical therapy in the randomized
trial, all study procedures were the same for participants in the randomized and observational
studies. Participants received treatment guided by protocols for surgical or nonsurgical care.
Those in the nonsurgical arms started with an initial set of treatments that included at least
active physical therapy, education/counseling with home exercise instruction, and a non-
steroidal anti-inflammatory drug if appropriate. For those nonsurgical participants with
inadequate initial response, participating clinicians chose additional physical, psychological,
and pharmacologic therapies from an extensive menu. Physicians had the discretion to choose
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specific therapies, including opioids, based on individual patients’ needs. For this analysis, we
included data from participants in both the randomized and observational studies.
Measures
At the time of enrollment, participants provided medical history, demographic, and lifestyle
information by interview and questionnaire. They reported the history of their spine condition
(including current and prior treatments), employment status, level of education achieved,
cigarette smoking, and any current or pending disability or legal action related to their spine
condition. Participants indicated whether they had ever received a diagnosis or were currently
receiving treatment for a list of medical problems. We derived a medical comorbidity count
using a list of 10 chronic conditions from this checklist: joint problems, coronary artery disease,
cancer, congestive heart failure, lung problem, diabetes, hypertension, liver problem, kidney
problem, and stroke.23 The checklist also assessed participants’ mental health, including single-
item queries about personal history of depression, anxiety or panic attacks, post-traumatic stress
(PTSD), alcoholism, or drug dependency.
Participants reported current medications for their spine condition and the frequency of use for
each medication. They also completed a battery of self-report measures, including the SF-36
Health Survey21;29 and the modified Oswestry Disability Index (American Academy of
Orthopaedic Surgeons/MODEMS version)8;12. Follow-up data were collected by
questionnaire and interview at 6 weeks and 3, 6, 12, and 24 months. At each time point, study
nurses assessed opioid and other medication use and patients completed the self-report
measures.
Pain was assessed with the SF-36 bodily pain subscale, which includes two items assessing
pain severity and interference. Mental health symptoms were assessed with the 5-item SF-36
mental health subscale. For SF-36 scales, responses are transformed into 0–100 subscale
scores, with lower scores indicating worse health.21;29 Back pain-related disability was
assessed with the modified Oswestry Disability Index, which assesses pain-related functional
limitations in 9 domains: getting dressed, lifting, walking/running, sitting, standing, sleeping,
social/recreational activities, traveling, and sexual activity.8;12 Impairment with each activity
is rated on a 6-point scale (from limitless/pain-free activity to complete limitation due to pain).
A total 0–100 score is calculated, with higher scores indicating worse disability.
Statistical analysis
We compared characteristics of participants with baseline self-reported opioid use with those
who reported no use at baseline using chi-square and t-tests for categorical and continuous
variables, respectively. We then used longitudinal models to evaluate potential predictors of
opioid use at follow-up. We refer to opioid use at follow-up as “continued” if participants also
reported opioid use at baseline and “incident” if they didn’t report use at baseline; however,
these terms may not be completely accurate because participants may have started or stopped
opioids before or between assessments. For all analyses, dichotomous opioid use indicators at
follow-up were the dependent variables.
We examined characteristics shown or hypothesized to be associated with opioid use as
potential predictors: pain severity (SF-36 bodily pain subscore); pain-related disability
(Oswestry Disability Index score); mental health (SF-36 mental health subscore); spine-related
disability claim or legal action (current or pending); current smoking; and receipt of spine
surgery. We analyzed the effect of non-operative or surgical treatment on an “as treated” basis.
Surgery status was a time-varying variable, meaning the value at each time point reflects the
subject’s surgery status at that follow-up assessment. We used baseline values for all other
potential predictor variables. Receipt of spine surgery, smoking status, and legal action were
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modeled as dichotomous variables, with surgery, non-smoking and no legal action,
respectively, as the reference groups. SF-36 subscales and Oswestry scores were divided into
tertiles and modeled as categorical variables. We designated the “healthiest” tertile (i.e., higher
values for SF-36 subscales, lower values for Oswestry) as the reference group.
We used generalized estimating equations (GEE)9 with a logit link to model opioid use
longitudinally measured during follow-up. Separate models were fit for users of opioids at
baseline to address “continued” long-term opioid use; and for non-users at baseline to address
incident opioid use. All models included adjustment for baseline variables representing
possible confounders and variables associated with missing data. This basic set of variables
included sociodemographic factors (age, sex, race, education, employment), medical
comorbidity count, study site, and spine diagnosis. First, we examined associations between
each potential predictor and opioid use, adjusted for the basic set of variables. Second, to
identify independent predictors of opioid use, we examined associations between each potential
predictor and follow-up opioid use in fully-adjusted models including all other potential
predictors. To confirm that it was appropriate to combine data across SPORT cohorts, we
examined analyses stratified in two ways: 1) by study enrollment (randomized trial and
observational cohort study) and 2) by diagnostic subgroups (IDH and SpS/DS). Analyses were
performed using SAS version 9.1 (SAS Institute, Inc., Cary, NC).
RESULTS
We included 2110 participants for whom data from at least one follow-up visit were available
(Figure 1). At baseline, 892 (42.3%) participants reported that they currently used opioids for
their spine condition, including 697 (33.0%) who reported daily opioid use and 195 (9.2%)
who reported less than daily use.
Associations with baseline opioid use
Table 1 shows characteristics of participants with and without self-reported opioid use at
baseline. Those reporting opioid use at baseline were more numerous in the IDH group,
younger, less likely to have any college education, less likely to be employed, more likely to
have applied for disability or pursued legal action, more likely to smoke, and more likely to
report a history of mental disorders compared with non-users. Baseline scores for all SF-36
scales and the Oswestry Disability Index were worse for opioid users than non-users.
We also examined baseline opioid use by diagnostic and study enrollment subgroups. Among
patients with IDH, those who chose to enroll in the observational study were more likely to
use opioids than those who agreed to be randomized (55% vs. 45%, p=0.001). Baseline opioid
use did not differ between observational and randomized patients for DS or SpS.
Predictors of long-term opioid use
Among participants who reported using opioids at baseline, 25% also reported opioid use at
12 months and 21% reported use at 24 months. Figure 2 shows the relationship between each
potential predictor and continued opioid use at follow-up, adjusted for the basic set of baseline
variables. Table 2 shows basic adjusted and fully-adjusted risk ratios (RR) for this long-term
continued opioid use at 12 and 24 months according to potential predictor variables. After
adjustment for the basic set of variables, nonsurgical treatment and smoking predicted opioid
use at both 12 and 24 months. In fully-adjusted models including all potential predictors, both
smoking (RR=1.9, p<0.001 at 12 months; RR=1.5, p=0.043 at 24 months) and non-surgical
treatment (RR=1.7, p=0.001 at 12 months; RR=1.8, p=0.003 at 24 months) predicted opioid
continuation. Disability/legal action, mental health, pain, and disability were not significant
predictors of continued opioid use at either follow-up time point.
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Results were similar when we examined models stratified by spine diagnosis (IDH and DS/
SpS) and study enrollment (randomized trial and observational study). Smoking and non-
surgical treatment were similarly predictive of continued opioid use at follow-up in stratified
analyses, but confidence intervals were wider and crossed 1.0 in some cases.
Predictors of incident opioid use
Among participants who reported no opioid use at baseline, 8% reported opioid use at 12
months and 7% at 24 months. Figure 3 shows the relationship between each potential predictor
and incident opioid use at all follow-up time-points, after adjustment for the basic set of baseline
variables. In both basic and fully-adjusted models, we found no significant predictors of
incident opioid use at 12 and 24 months.
In models stratified by study enrollment, we found no significant associations between
predictor variables and incident opioid use among randomized trial participants. Among
participants in the observational study, choosing nonsurgical treatment predicted significantly
less incident opioid use only at 24 months (fully adjusted RR=0.7, p=0.10 at 12 months;
RR=0.5, p=0.025 at 24 months).
In models stratified by spine diagnosis, we found no significant associations between predictor
variables and incident opioid use among participants with DS/SpS. Among those with IDH,
nonsurgical treatment predicted less incident opioid use at 12, but not 24, months (fully adjusted
RR=0.3, p=0.004 at 12 months; RR=0.8, p=0.59 at 24 months).
DISCUSSION
To our knowledge, this is the first longitudinal study to prospectively assess predictors of opioid
use in a population of patients with pain. We found that nonsurgical treatment and smoking
independently predicted continued long-term opioid use among patients reporting opioid use
at baseline, whereas pain severity, pain-related disability, mental health, and spine-related
legal/disability status did not.
The rate of opioid use at baseline was at the high end of prevalence rates reported in the
literature;20 long-term continuation rates were also impressive, although opioid use declined
steadily over the two year study period. The prevalence of opioid use at baseline was much
higher in SPORT (42.3%) than in a cross-sectional study by Fanciullo et al. (3.4%) that also
evaluated patients seen at spine specialty centers.13 Enrollment of spine center patients with
sufficient pain to be candidates for surgery may explain the greater prevalence of opioid use
in SPORT. Additionally, opioid prescribing for non-cancer pain became generally more
common in the years between the Fanciullo et al. study (1995–1998) and SPORT baseline
assessments (2000–2003).18;22;35 Our findings that baseline opioid use was associated with
sociodemographic factors and worse pain, function, and quality of life are consistent with the
literature. Unlike some previous studies,6;16 we did not find evidence of racial disparities in
opioid use.
We found a striking association between smoking and self-reported opioid use, in that baseline
cigarette smoking independently predicted continued long-term opioid use. Prior cross-
sectional studies have found an association between smoking and greater opioid use in spine
center patients13 and workers with back injury.24 Longitudinal studies have found that smokers
may be at risk for worse outcomes14 and adherence17 in multidisciplinary pain treatment
programs. Worse nonsurgical pain treatment response or adherence among smokers is one
potential explanation for our finding. Another possible explanation is confounding by
substance use disorders. Most studies of smoking and opioid use have not controlled for drug
or alcohol abuse, which are more prevalent in smokers; therefore, smoking may be a marker
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of substance use disorders in these populations. We were unable to control for substance use
disorders because participants were not assessed with adequately sensitive measures of drug
or alcohol use.
In this study, patients who received surgical treatment were less likely to continue opioid use
on a long-term basis than those who didn’t receive surgery. This finding supports SPORT’s
primary results,31–34 which showed a symptomatic benefit for surgery, and suggests a potential
additional benefit for patients considering surgery. Risks of opioid use for longer than 1–2
years are not yet adequately understood, but may include hypogonadism, increased fracture
risk, opioid-induced hyperalgesia, substance use disorders, and central sleep apnea, in addition
to immediate side effects such as constipation and sedation.1;2;7;11;30 Given these potential
risks and the practical difficulties of long-term opioid prescribing experienced by both
prescribers and patients, information about decreased opioid use after surgery could potentially
be useful in surgical decision-making. Although the balance of risks and benefits associated
with long-term opioids is not clear, for some patients with well-defined spine conditions, the
risk of continued pain management with opioids may outweigh the risk of surgery. The
likelihood of requiring long-term opioid use and the attendant potential for adverse
consequences of this use could be provided to patients considering spine surgery to help them
make better informed decisions.
The relationship between surgery and incident opioid use is less clear. A peak in incident opioid
use was evident in the initial months of study, representing expected new use in the acute
postoperative period; however, results for incident use at 12 and 24 months were conflicting.
We found no significant predictors of incident use among participants who were in the
randomized trial, but among those who declined randomization and enrolled in the
observational study, nonsurgical treatment predicted less incident opioid use. Selection bias is
a likely explanation for this finding (i.e., participants in the observational study who had less
pain or were improving with conservative therapy were less likely to choose to undergo surgery
and to start opioids). We also found a difference in incident use patterns between diagnostic
strata. We found no predictors of incident opioid use among participants with DS/SpS, but
among those with IDH, non-surgical treatment was associated with less incident use at 12 (not
24) months. Overall, results suggest that patients who received incident post-operative opioids
discontinued them as expected.
We were surprised that, although mental health symptoms were strongly associated with opioid
use at baseline, they did not predict future opioid use (continued or incident) in our models.
These results differ from those of a prior longitudinal study by Sullivan et al., which found that
problem drug use and mental disorders independently predicted opioid use in the general
population.26 Differences between the studies may explain the discrepant results. SPORT
enrolled a clinically well-defined population of patients with confirmed spinal pathology who
had been referred to spine specialty centers, whereas Sullivan et al. used data from the
Healthcare for Communities (HCC) survey, which enrolled members of the general population.
The majority of HCC participants did not have pain, and those who did had a diverse collection
of painful conditions. It may be that mental health is a stronger predictor of opioid use in a
diverse population than in a population of patients with well-defined spine pathology. Another
possibility is that the difference in results reflects a difference in measurement: we used tertiles
of the SF mental health subscale as our measure of mental health symptoms, whereas the HCC
survey used the presence of specific mental health disorders derived from a diagnostic
interview. Less likely, the association of mental health with opioid use in Sullivan et al. may
be due to confounding by pain severity.
Strengths of this study include our use of prospective longitudinal data from a large, well-
defined population of patients with back pain due to common spine conditions. Opioid use was
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common in this study population and we had detailed demographic and clinical data, allowing
us to control for multiple potentially confounding factors in our analysis. To our knowledge,
this is the first longitudinal study to assess predictors of opioid use among patients with specific
lumbar spine disorders.
This study does have several limitations. First, as with all observational studies, our results
may be affected by unmeasured differences between opioid users and non-users. For example,
drug and alcohol use were not fully assessed, so we were unable to evaluate substance use
problems as predictors of opioid use. Patients were asked at baseline to indicate whether they
had been diagnosed or treated for “alcoholism” or “drug dependency,” but were not formally
assessed for current or past substance use disorders. Fewer than 2% of participants endorsed
a history of alcoholism or drug dependency, which is likely to be a substantial underestimation
of the true prevalence. Second, we were unable to assess use of specific opioid medications
and doses used by SPORT participants. Medications used for the spine condition were assessed
at each visit, but only the frequency of use for each medication class was recorded. Finally,
results may not be generalizable to all patients with back pain or other chronic pain conditions.
The SPORT study population included patients who had one of three well-defined spine
conditions; patients with nonspecific back pain and those with pain due to other spine
conditions were not included.
In conclusion, in this prospective study of self-reported opioid use among patients with
common spine conditions, we found that nonsurgical treatment and smoking predicted long-
term continuation of opioid use. The greater use of long-term opioids among patients who
received nonsurgical therapy may be a factor worth considering in surgical decision-making
for patients with disc herniation or spinal stenosis. To better understand the causes and
consequences of long-term opioid use, future research should focus on untangling the complex
longitudinal relationship between opioid use and mental health and substance use disorders,
including smoking, among people with chronic pain.
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Figure 2. Percentage of participants with baseline opioid use reporting use at each follow-up time-
point (n=892)
MH = SF-36 mental health subscale, BP = SF-36 bodily pain subscale, ODI = Oswestry
Disability Index. Figures show percentages with 95% confidence intervals, adjusted for age,
sex, race, education, employment, baseline duration of spine problem, medical comorbidity
count, study site, and spine diagnosis. SF-36 subscale scores and Oswestry scores are divided
into tertiles.
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Figure 3. Percentage of participants with no baseline opioid use reporting use at each follow-up
time-point (n=1218)
MH = SF-36 mental health subscale, BP = SF-36 bodily pain subscale, ODI = Oswestry
Disability Index. Figures show percentages with 95% confidence intervals, adjusted for age,
sex, race, education, employment, baseline duration of spine problem, medical comorbidity
count, study site, and spine diagnosis. SF-36 subscale scores and Oswestry scores are divided
into tertiles.
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Table 1
Characteristics of participants with and without opioid analgesic use at baseline
Characteristic
Baseline opioid use (n
= 892)
No baseline opioid use
(n = 1218) P value*
Age, mean years (SD) 50.6 (15.6) 55.5 (16.1) <0.001
Female sex, n (%) 466 (52%) 590 (48%) 0.09
Race, n (%)
 White 762 (85%) 1037 (85%) 0.97
 Black 71 (8%) 97 (8%)
 Other 59 (7%) 84 (7%)
Education—at least some college, n (%) 583 (66%) 875 (73%) 0.003
Employment, n (%)
 Working full or part time 389 (44%) 580 (48%) <0.001
 Disabled 155 (17%) 95 (8%)
 Retired or other 347 (39%) 543 (45%)
Disability application or payments, n (%)‡ 187 (21%) 126 (10%) <0.001
Legal action related to spine problem, n (%)† 60 (7%) 49 (4%) 0.007
Current smoking, n (%) 196 (22%) 164 (14%) <0.001
Number of medical comorbidities, mean (SD)
§
0.93 (1.1) 1.0 (1.1) 0.09
Depression history, n (%) 136 (15%) 140 (12%) 0.01
Anxiety or PTSD history, n (%) 83 (9%) 58 (5%) <0.001
Alcohol or drug dependence history, n(%) 20 (2.2%) 17 (1.4%) 0.20
Spine Diagnosis
 IDH, n (%) 540 (61%) 520 (43%) <0.001
 SS/DS, n (%) 352 (39%) 698 (57%)
Duration of spine problem > 6 months, n (%)
 Acute (≤ 6 weeks) 80 (9%) 80 (7%) <0.001
 Sub-acute (> 6 weeks to 6 months) 496 (56% 607 (50%)
 Chronic (> 6 months) 316 (35%) 531 (44%)
SF-36
 Bodily Pain subscale, mean (SD) 21.1 (14.1) 32.4 (17.7) <0.001
 Physical Function subscale, mean (SD) 27.8 (22.0) 40.5 (23.8) <0.001
 Mental Health subscale, mean (SD) 61.0 (20.3) 69.3 (19.0) <0.001
 Physical Component Score, mean (SD) 27.2 (7.2) 31.2 (8.2) <0.001
 Mental Component Score, mean (SD) 44.3 (11.8) 49.0 (11.6) <0.001
Oswestry Disability Index, mean (SD) 55.5 (18.4) 40.8 (18.6) <0.001
*
P value for unadjusted comparison between participants reporting any opioid use and those reporting no opioid use
†
Affirmative response to the following: “Have you brought any legal action related to your spine-related problem?”
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‡
Affirmative response to the following: “Have you applied to or are you now receiving payments from either Worker’s Compensation, Social Security
Disability, or any other disability insurance programs for your spine-related problem?”
§
Number of medical comorbidities is the count of problems from the following list: hypertension, diabetes, joint problems, coronary artery disease,
cancer, congestive heart failure, lung problem, diabetes, liver problem, kidney problem, stroke (possible range 0–10).
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